InVivoMAb anti-mouse CLEC9A (CD370)
BE0305
ApplicationsFlow Cytometry, ImmunoFluorescence, ImmunoPrecipitation, Western Blot, ELISA, Neutralisation/Blocking, Other Application
Product group Antibodies
ReactivityMouse
Overview
- SupplierBio X Cell
- Product NameInVivoMAb anti-mouse CLEC9A (CD370)
- Delivery Days Customer7
- ApplicationsFlow Cytometry, ImmunoFluorescence, ImmunoPrecipitation, Western Blot, ELISA, Neutralisation/Blocking, Other Application
- CertificationResearch Use Only
- ClonalityMonoclonal
- Clone ID7H11
- Concentration4-11 mg/ml
- Estimated Purity>95%
- HostRat
- IsotypeIgG1
- ReactivityMouse
- Storage Instruction2°C to 8°C
- UNSPSC12352203
References
- Snyder AG, Hubbard NW, Messmer MN, et al. Intratumoral activation of the necroptotic pathway components RIPK1 and RIPK3 potentiates antitumor immunity. Sci Immunol. 2019,4(36). doi: 10.1126/sciimmunol.aaw2004Read this paper
- Picco G, Beatson R, Taylor-Papadimitriou J, et al. Targeting DNGR-1 (CLEC9A) with antibody/MUC1 peptide conjugates as a vaccine for carcinomas. Eur J Immunol. 2014,44(7):1947-55. doi: 10.1002/eji.201344076Read this paper
- Joffre OP, Sancho D, Zelenay S, et al. Efficient and versatile manipulation of the peripheral CD4+ T-cell compartment by antigen targeting to DNGR-1/CLEC9A. Eur J Immunol. 2010,40(5):1255-65. doi: 10.1002/eji.201040419Read this paper
- Sancho D, Mourão-Sá D, Joffre OP, et al. Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. J Clin Invest. 2008,118(6):2098-110. doi: 10.1172/JCI34584Read this paper
Datasheet
Related products
Product group Antibodies
References
- SizePrice